La vendita allo scoperto per Cosmo Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cosmo Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cosmo Pharmaceuticals (OTC:CMOPF) Azioni, Report sulle vendite allo scoperto

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

COSMO PHARMA NV ORD by Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

WIIM

APLD

Applied Digital shares are trading higher after B. Riley Securities raised its price target on the stock from $8 to $15.

ACLS

ALAR

ALGM

AMBA

AMKR

AOSL

AVGO

BZAI

CEVA

CRDO

DIOD

ENTG

KLIC

MCHP

MKSI

MOBX

MPWR

NVDA

NVTS

NXPI

OLED

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

WOLF

Shares of several semiconductor companies are trading higher amid GlobalFoundries' announcement to commit $16 billion towards US chip expansion, which may be buoying investor sentiment towards the space.

JP Morgan analyst Mark R Murphy <a href="https://www.benzinga.com/quote/DOCU/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Neutral rating</a> on DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a price forecast of $81 on Tuesday.
Heading into DocuSign&#8217;s fiscal first-quarter earnings report, Murphy maintained a cautiously optimistic view, expecting the company to deliver relatively stable execution despite a dynamic-but-manageable macro environment.
The analyst noted that DocuSign&#8217;s recent pattern of fairly conservative guidance sets the company up well to deliver upside to current fiscal first-quarter estimates, while still likely allowing it to maintain some cushion for the back-half of the year to account for ongoing macroeconomic and geopolitical volatility.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
He continues to sense a more balanced risk-reward profile for DocuSign in the medium term, with Intelligent Agreement Management (IAM) traction continuing to drive some stabilization and improvement in growth rates. This is partially balanced by an inferior GAAP profitability framework amid an ongoing IAM investment cycle and some exposure to macro-sensitive end-markets.
Murphy noted that DocuSign is well positioned to meet or exceed its fiscal first-quarter guidance bar, calling for +6% CC revenue and proforma billings growth. Both of these call for some deceleration versus the prior quarter, though they include some leap year impact.
While DocuSign may elect not to entirely pass through any fiscal first-quarter upside nor incremental currency favorability to the full-year guidance, similar to peers, the analyst noted this could create a favorable setup for the second half, particularly as IAM contributions continue to feather in. Partially balancing this, Murphy said that DocuSign&#8217;s fiscal 2026 outlook assumes consistent macro trends relative to when it was provided in mid-March. As a result, any degradation in underlying demand activity could exert some drag against ongoing improvements in the core business and go-to-market efforts.
While the analyst noted the potential for some continued variability in key metrics, such as customer adds and DNR, he continued to monitor for commentary related to envelopes sent and consumption, for which the company&#8217;s indications have been encouraging in recent quarters, to assess the underlying health of the core business, including in more macro-volatile verticals and geographies. In addition, coming off DocuSign Momentum, where the company highlighted new AI-driven products such as AI Contract Agents backed by its Iris AI engine, Murphy remains focused on DocuSign&#8217;s ability to drive further upsell and diversification from its core eSign base through newer features, likely to aid retention trends over time.
As a reminder, DocuSign also commented that it expects this IAM contribution to grow in fiscal 2026 and represent a &#8220;low-double-digit&#8221; percentage share of its total subscription recurring book of business (ARR) by the fiscal fourth quarter.
Overall, Murphy remains encouraged by the pacing of adoption for this broader IAM platform, which has aligned with his view of an accelerated adoption cycle relative to contract lifecycle management (CLM). 
He noted that much of the penetration today has been in the small and mid-market segments, with the enterprise segment and self-serve motion likely to ramp gradually as the year progresses.
As a reminder, DocuSign disclosed at its Momentum conference in April that over 10K customers had purchased IAM.
The analyst noted that IAM adoption by a &#8220;low-double-digit&#8221; share of the total Subs ARR base by year-end could drive a fairly meaningful uplift in the spending of existing eSign users, potentially resulting in a low-single-digit tailwind to growth trends in the medium-term.
Overall, Murphy noted this as a fairly tepid reading on balance when evaluated on a Y/Y growth basis, though he noted that these results for the first quarter land above five of the past ten quarters.
While an informative additional data point, he cautioned investors from over-indexing these web traffic figures, given the volatility in these metrics and an absence of supporting transaction-based trends within this data.
Murphy projected first-quarter revenue of $747 million and adjusted EPS of $0.82.
Price Action: DOCU stock is trading higher by 1.10% to $92.62 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image via Shutterstock

News

Price Target

Reiteration

Analyst Ratings

DOCU

DocuSign Macro Risks Could Cap Upside Despite AI, IAM Traction: Analyst

TD Securities analyst Aaron Bilkoski maintains Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) with a Buy and raises the price target from $57 to $58.

VNOM

TD Securities Maintains Buy on Viper Energy, Raises Price Target to $58

TD Securities analyst Sean Steuart maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Hold and raises the price target from $6 to $6.5.

TD Securities Maintains Hold on Algonquin Power, Raises Price Target to $6.5

Guidance

VSCO

CORRECTION: Victoria's Secret & Co Sees Q1 2025 Net Sales Of $1.35B Vs $1.42B Estimate; Adj. EPS Of $0.09 Vs $0.04 Estimate

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to hover near key resistance, with traders closely watching support levels to avoid a <a href="http://deeper summer correction">deeper summer correction</a>.
What Happened: In an update in his <a href="https://www.patreon.com/c/KevCapitalTA/posts">exclusive Patreon group</a>, prominent analyst Kevin highlighted that BTC has once again failed to break above the $106,800 resistance, a level that aligns with the macro 1.703 Fibonacci extension. 
After a 50% rally from cycle lows without a significant pullback, rejection at this level was anticipated.
Kevin pointed to recent golden crosses on both the daily and weekly timeframes (50/200 SMA and 21 EMA/20 SMA), typically followed by 7–10% corrections, and occasionally deeper ones. 
A fresh weekly hash ribbon buy signal—a historically reliable bullish indicator, has also flashed but often precedes short-term dips before upside continuation.
Despite bullish technical setups, Kevin noted mixed macro conditions and seasonal weakness in crypto markets. 
If Bitcoin fails to hold support between $100,000–$103,000, it could slide into a prolonged correction. 
If support holds, BTC could finally break through $106,800 and resume its upward trend.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45772932/bitcoins-post-golden-cross-correction-playing-out-benjamin-cowen-flags-signs-of-q3-weakness">Bitcoin&#8217;s Post-Golden Cross Correction Playing Out — Benjamin Cowen Flags Signs Of Q3 Weakness</a>
Why It Matters: Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1930293971370291252">echoed</a> the uncertain near-term outlook, emphasizing that Bitcoin&#8217;s price has reliably followed a 4-year halving cycle, whether measured top-to-top or bottom-to-bottom.
He pushed back against speculation that this cycle will behave differently due to ETFs or broader market maturity, arguing that such claims were made in prior cycles too. 
"Skepticism about the cycle actually strengthens it," he said, reaffirming his plan to scale out of positions gradually through late 2025, just as he did in the 2021 cycle peak.
What's Next: Traders now look to the $100,000–$103,000 zone as a critical line in the sand. 
A breakdown could open the door to a summer slump, while a rebound might trigger a breakout above resistance, potentially setting the stage for a fresh leg up.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45767169/bitcoin-ethereum-xrp-dogecoin-tick-up-as-battle-for-105000-intensifies">Bitcoin, Ethereum, XRP, Dogecoin Tick Up As &#8216;Battle For $105,000&#8217; Intensifies</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Stuck At $105,000: What Does Technical Analysis Say?

SSRM

SSR Mining shares are trading lower after the company announced its operations at Seabee have been temporarily suspended.

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Upgrades

Health Care

Movers

Trading Ideas

General

ABBV

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Peloton Interactive, Inc. shares are trading higher Wednesday. On Tuesday, a report suggested the company is launching a resale market for used bikes and treadmills.
The Details: According to <a href="https://www.cnbc.com/2025/06/03/peloton-launching-resale-market-for-used-bikes-treadmills.html">CNBC</a>, Peloton has rolled out Repowered, a platform that lets users list their used equipment and apparel, with pricing guidance provided by a generative artificial intelligence tool.
Sellers will receive 70% of the sale price, with the remainder shared between Peloton and its resale partner Archive. They will also get a discount toward new equipment. Buyers will benefit from a lower activation fee, which the company said is dropping from $95 to $45 for used products. 
Peloton said buyers will be able to view the equipment's history on the listing and can choose to have it delivered for an additional fee.
The company also said that as of last summer, connected fitness subscriptions from customers who purchased hardware through secondary channels were up 16% year-over-year.
Repowered launched as a beta version in New York City, Boston and Washington D.C., with plans to expand across the United States in the coming months.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
PTON Price Action: At the time of writing, Peloton shares are trading 11.2% higher at $7.40, according to data from Benzinga Pro.
Image: via Shutterstock

PTON

Peloton Stock Is Climbing Higher Wednesday: What's Going On?

<a href="https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942">https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942</a>

'Meta Seeks Hollywood Deals for New Virtual-Reality Headset'- WSJ

Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading higher Wednesday following its announcement that it&#8217;s no longer subject to asset growth restrictions that were <a href="https://www.benzinga.com//node/45758069">imposed in 2018</a>.
What To Know: On Tuesday, Wells Fargo said the Federal Reserve lifted the asset cap that had been in place since 2018, a penalty tied to the bank's fake-account scandal, according to the <a href="https://apnews.com/article/wells-fargo-federal-reserve-sales-practices-assets-e1d79548c0da446320c441e88de3eea4">Associated Press</a>.
The Federal Reserve&#8217;s decision to lift the asset cap marks a pivotal milestone in our journey to transform Wells Fargo. We are a different and far stronger company today because of the work we&#8217;ve done,&#8221; said Wells Fargo CEO Charlie Scharf.&nbsp;
The fake-accounts scandal, which erupted in 2018, stemmed from a high-pressure sales culture that led employees to open millions of unauthorized accounts in an effort to meet aggressive performance goals.
Since taking the helm in 2019, Scharf has worked to convince regulators that Wells Fargo has overhauled its practices and addressed longstanding compliance failures.
&#8220;In addition, we have changed and simplified our business mix, and we have transformed the management team and how we run the company. We have been methodically investing in the company&#8217;s future while improving our financial results and profile,&#8221; Scharf added.
&#8220;We are excited to continue to move forward with plans to further increase returns and growth in a deliberate manner supported by the processes and cultural changes we have made.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a>
WFC Price Action: At the time of publication, Wells Fargo stock is trading 0.41% higher at $75.96, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjk9-eNmtiNAxWxg4kEHSKNIm4QFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image: via Shutterstock

Wells Fargo Stock Is Trading Higher Wednesday: What's Going On?

<a href="https://x.com/pulte/status/1930323713154789718">https://x.com/pulte/status/1930323713154789718</a>

U.S. Director Of Federal Housing FHFA Pulte Posts On X "I am meeting with the Equifax CEO today, it should be an interesting meeting. I also had a great meeting with the National Association of Realtors and much more"

Roth Capital analyst George Kelly reiterates Mama's Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) with a Buy and raises the price target from $9 to $10.

MAMA

Roth Capital Reiterates Buy on Mama's Creations, Raises Price Target to $10

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/06/2025-06-04_08h29_43.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Stock Market Magnet</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-stock-market-magnet-trump-budget-spy-mc-06042025">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul class="wp-block-list">
<li>The chart shows that the pull of zone 1 as the stock market's magnet is very strong.</li>
<li>The chart shows that RSI has now become barely overbought.&nbsp; This indicates that there is room for the stock market to move to zone 1, but the stock market can also pull back due to overbought conditions.</li>
<li>Elon Musk is calling President Trump's budget a "disgusting abomination."&nbsp; Musk says, "Congress is making America bankrupt." Musk claims that President Trump's "One Big Beautiful Bill" will massively increase the budget deficit to $2.5T. 
<ul class="wp-block-list">
<li>The momo crowd buys Tesla Inc (TSLA) stock on every comment from Musk.  How is the momo crowd reacting to Musk's comment about President Trump's budget?  The momo crowd is aggressively buying stocks as the pull of the zone 1 magnet in the stock market is much stronger than Musk's influence.</li>
<li>Prudent investors should pay attention to Musk's comment about President Trump's budget.&nbsp; After all, Musk spent $250M of his own money to get Trump elected and countless hours in Washington on DOGE to help President Trump.</li>
</ul>
</li>
<li>President Trump said, "I like President XI of China, always have, and always will, but he is VERY TOUGH, AND EXTREMELY HARD TO MAKE A DEAL WITH!!!" 
<ul class="wp-block-list">
<li>How does the momo crowd react to President Trump's statement?&nbsp; The momo crowd is buying stocks because President Trump likes President Xi, and they are ignoring President Trump saying that President Xi is extremely hard to make a deal with.</li>
<li>Prudent investors should not ignore half of President Trump's statement.</li>
</ul>
</li>
<li>Automatic Data Processing Inc (ADP) is the largest private payroll processor in the country.   ADP data poured cold water on all the bullishness.  ADP showed employment much weaker than expected.  ADP Employment Change came at 37K vs. 115K consensus. 
<ul class="wp-block-list">
<li>Weak ADP data brought quick selling to the stock market, but as of this writing, the momo crowd is aggressively buying the shallow dip caused by the ADP data.</li>
</ul>
</li>
<li>ADP data comes after JOLTS data.&nbsp; JOLTS came at 7.391M vs. 7.2M prior.&nbsp; JOLTS data contributed to yesterday's stock market rally.</li>
<li>Initial jobless claims will be released tomorrow at 8:30am ET and the official jobs report will be released Friday at 8:30am ET.</li>
<li>ISM Services was released today at 10am ET.  ISM Services data can cause major moves in the markets.  ISM Services data is a leading indicator and carries heavy weight in the adaptive <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> with a long proven track record with inputs in <a href="https://thearorareport.com/unique-zyx-asset-allocation-4/">10 categories</a>.</li>
<li>The Fed's Beige Book will be released today at 2pm ET and may be market moving.</li>
<li>There has been significant Fed speak: 
<ul class="wp-block-list">
<li>Dallas Fed President Logan said the Fed should focus on forward looking policy that is prepared for a high inflation era.</li>
<li>Fed Governor Cook warned of increasing uncertainty with trade policy potentially pressuring inflation and jobs.</li>
<li>Atlanta Fed President Bostic indicated room for one rate cut in 2025.</li>
</ul>
</li>
<li>For the AI trade,  earnings from Broadcom Inc (AVGO) are important.  Earnings will be released after market close.</li>
<li>Also important are earnings from Lululemon Athletica Inc (LULU) as it will give a glimpse into the state of the higher end consumer as well as lower end consumers who purchase Lululemon as a status symbol.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Meta Platforms Inc (META) and NVIDIA Corp (NVDA).
In the early trade, money flows are neutral in Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Microsoft Corp (MSFT), and TSLA.
In the early trade, money flows are negative in Apple Inc (AAPL).
In the early trade, money flows are like a yoyo in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Oil</h4>
API crude inventories came at a draw of 3.3M barrels vs. a consensus of a draw of 0.9M barrels.&nbsp; This data is bearish for oil, but new politics will trump any data.
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Long Ideas

Market Summary

Broad U.S. Equity ETFs

Opinion

Markets

Pull Of Stock Market Magnet Stronger Than Musk Calling Trump's Budget A "Disgusting Abomination"

<a href="https://www.federalreserve.gov/monetarypolicy/beigebook202505-summary.htm">https://www.federalreserve.gov/monetarypolicy/beigebook202505-summary.htm</a>

Macro Economic Events

Macro Notification

Econ #s

Economics

Fed Beige Book: This Report Was Prepared At The Federal Reserve Bank of ST.; Reports Across the Twelve Federal Reserve Districts Indicate That Economic Activity Has Declined Slightly Since the Previous Report; However, a Few District Reports Indicate the Outlook Has Deteriorated While a Few Others Indicate the Outlook Has Improved; Prices Have Increased at a Moderate Pace Since the Previous Report

Citigroup analyst Paul Lejuez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy and lowers the price target from $60 to $55.

Citigroup Maintains Buy on Academy Sports, Lowers Price Target to $55

Roth Capital analyst Matt Koranda reiterates Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) with a Buy and raises the price target from $2.5 to $3.

SPWH

Roth Capital Reiterates Buy on Sportsman's Warehouse, Raises Price Target to $3

During the last three months, 15 analysts shared their evaluations of Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Wells Fargo and provided 12-month price targets. The average target is $81.23, accompanied by a high estimate of $90.00 and a low estimate of $73.00. A 0.56% drop is evident in the current average compared to the previous average price target of $81.69. 
<img src="https://www.benzinga.com/files/images/story/2025/1749060099_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Wells Fargo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$78.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Vivek Juneja</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.50</td>
<td>$82.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Wells Fargo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wells Fargo compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Wells Fargo's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Wells Fargo's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WFC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Wells Fargo analyst ratings.</a>
<h2>About Wells Fargo</h2>
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US
<h3>Understanding the Numbers: Wells Fargo's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Wells Fargo's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.42%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Wells Fargo's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Wells Fargo's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.86%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Wells Fargo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.16.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Wells Fargo Stock

Analysts' ratings for Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.33, a high estimate of $45.00, and a low estimate of $38.00. A 2.06% drop is evident in the current average compared to the previous average price target of $42.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1749060084_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Valvoline among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason English</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Chasen Bender</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Valvoline. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Valvoline compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Valvoline's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Valvoline's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Valvoline analyst ratings.</a>
<h2>Discovering Valvoline: A Closer Look</h2>
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
<h3>Financial Insights: Valvoline</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Valvoline's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 3.73%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Valvoline's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Valvoline's ROE excels beyond industry benchmarks, reaching 15.72%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Valvoline's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: Valvoline's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.51, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Cosmo Pharmaceuticals

Vendite allo scoperto

Cosmo Pharmaceuticals (OTC:CMOPF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO